



## BUY Opus One 2014: One of the New World's Best Performing Wines

Price (6x75cl)	<b>\$2,725</b>
Cru Investment Rating	<b>"AAA"</b>
Average Score <sup>1</sup>	<b>96</b>
Price per Point	<b>\$28.3</b>
Drink Date	<b>2019-2047</b>
Price Target (6x75cl) over 24 months	<b>\$3,340</b>
Implied price performance	<b>23%</b>

- **Opus One** is one of **California's very top fine wines**. The 2014 is one of the best 5 vintages of the last 35 vintages released, according to critics.
- **Opus One 2014 is the lowest priced** of any Opus vintage available.
- Opus One has seen an **average Compound Annual Growth Rate (CAGR) of 15.8%** from the 2001-2014 vintages (buying on release and holding until now).
- Opus One is a **winery with momentum**; quality is improving year on year and **global demand is rising**.

**Opus One** is a joint venture between legendary local winemaker American **Robert Mondavi** and Bordeaux's famous **Baron Philippe de Rothschild** (of Mouton Rothschild). When they created the new wine (conceived in 1970) their aim was to create a Californian wine to **rival the very best from Bordeaux**, using a 'Bordeaux Blend' of predominantly Cabernet Sauvignon and 100% French Oak. Since the first vintage (1979) was released in 1983 Opus has grown in acclaim, particularly in the last 10 years when the wine has excelled. Crucially for long-term collectors, the wine is distributed through Bordeaux's 'negociant' system, which means that it is promoted around the world by the same network with sells Lafite, Petrus, Le Pin, Mouton-Rothschild etc. Opus One's excellent price performance in the last ten years means that it has truly come of age as a long-term investable wine.

### Opus One 2014 is the Best Value of any Vintage


Opus One 2014 is the lowest price of any vintage of Opus One available. Its 'price per point' of only \$28.3 per case (\$2,725 / 96) also means that it represents the best value per unit of critic score of any vintage.

Wine	Av. Score	Price	% Diff to 2014	Price per pt.
2014	96	\$ 2,725	-	\$ 28.3
2013	98	\$ 2,915	6.98%	\$ 29.7
2012	96	\$ 2,920	7.16%	\$ 30.4
2011	96	\$ 2,925	7.34%	\$ 30.6
2010	96	\$ 3,100	13.76%	\$ 32.2
2009	94	\$ 2,970	8.99%	\$ 31.7
2008	95	\$ 3,215	17.98%	\$ 34.0
2007	94	\$ 3,100	13.76%	\$ 33.2
2006	93	\$ 2,960	8.62%	\$ 32.0
2005	93	\$ 3,980	46.06%	\$ 42.6
2004	94	\$ 3,790	39.08%	\$ 40.4

<sup>1</sup> (Wine Advocate, James Suckling and Antonio Galloni's Vinous.)

## Opus One: One the New World's Most Collectable Wines

**Opus One** has seen a **significant rise in demand** and **prices** in recent years. Release prices have increased around 100% in 10 years. This has been driven by the increased quality of the wine and a significant improvement in critical acclaim since the early 2000s. **The last 5 vintages of Opus released are the best ever released.** The 2015 vintage, likely released in Autumn 2018, is set to continue this trend with an average critic score of 97 points.



Opus One's quality now rivals that of the great Bordeaux estates on which it is modelled.

## Opus One has an Excellent Records of Returns

Although release prices have gone up, recent vintages of Opus One have also seen the highest returns in value as global demand has surged. Opus One has an average Compound Annual Growth Rate (CAGR) of 15.8% since 2001 (buying on release and holding until now). This remarkable rate shows that not only recent vintages have benefitted from the wine's growing popularity. Opus One has rewarded 'buy and hold' collectors handsomely.

Wine	Av. Score	Price	CAGR
2014	96	\$ 2,725	-
2013	98	\$ 2,915	31.2%
2012	96	\$ 2,920	27.5%
2011	96	\$ 2,925	18.6%
2010	96	\$ 3,100	16.6%
2009	94	\$ 2,970	13.7%
2008	95	\$ 3,215	12.4%
2007	94	\$ 3,100	11.7%
2006	93	\$ 2,960	10.7%
2005	93	\$ 3,980	13.4%
2004	94	\$ 3,790	13.4%
2003	93	\$ 3,675	13.3%
2002	95	\$ 3,270	11.2%
2001	91	\$ 3,190	11.0%
<b>Average</b>	<b>94</b>	<b>\$ 3,195</b>	<b>15.8%</b>

Taking an average of similar quality vintages, (those with an average score of 95-98 points,) **the average CAGR rises to 20%**. Based on the historical performance of Opus One post release, we expect the 2014 to continue to gain value at least 10.7% per annum over a 2 year period. This gives us a **price target of \$3,340** (6x75cl) and an **implied price performance of 23% over 24 months**.

## IMPORTANT NOTICE

This report has been issued or approved for issue by an entity forming part of Cru (as defined below) and has been forwarded to you solely for your information and should not be considered as an offer or solicitation of an offer to sell, buy or subscribe to any securities or any derivative instrument or any other rights pertaining thereto ("financial instruments"). Cru is not authorised by the Financial Conduct Authority in the United Kingdom to offer investment advice or to make investment recommendations. This note does not represent investment advice or an investment recommendation. This report is intended for use by professional or business clients only. This report may not be reproduced without the consent of Cru.

The information and opinions expressed in this report have been compiled from sources believed to be reliable, but, neither Cru, nor any of its directors, officers, or employees accepts liability from any loss arising from the use hereof or makes any representations as to its accuracy and completeness. Any opinions, forecasts or estimates herein constitute a judgement as at the date of this report. There can be no assurance that future results or events will be consistent with any such opinions, forecasts or estimates. Past performance should not be taken as an indication or guarantee of future performance, and no representation or warranty, express or implied is made regarding future performance. This information is subject to change without notice, its accuracy is not guaranteed, it may be incomplete or condensed and it may not contain all material information concerning the product or products mentioned. Cru is not agreeing to nor is it required to update the opinions, forecasts or estimates contained herein.

The value of any products mentioned in this report can fall as well as rise. Foreign currency denominated products are subject to fluctuations in exchange rates that may have a positive or adverse effect on the value, price or income of such products.

This report does not have regard to the specific instrument objectives, financial situation and the particular needs of any specific person who may receive this report. Investors should seek financial advice regarding the appropriateness of investing in any products or investment strategies discussed in this report.

Cru (or its directors, officers or employees) may, to the extent permitted by law, own or have a position in the products of any company or related company or products referred to herein, and may add to or dispose of any such position or may make a market or act as a principal in any transaction in such products. Directors of Cru may also be directors of any of the companies mentioned in this report. Cru (or its directors, officers or employees) may, to the extent permitted by law, act upon or use the information or opinions presented herein, or research or analysis on which they are based prior to the material being published. Cru may have issued other reports that are inconsistent with, and reach different conclusions from, the information presented in this report. Those reports reflect the different assumptions, views and analytical methods of the analysts who prepared them.

For the purposes of this disclaimer, "Cru" shall mean: (i) Cru London Limited; (ii) Cru Asia Limited and (iii) from time to time, in relation to Cru London Limited and/or Cru Asia Limited, the ultimate holding company of that entity, a subsidiary (or a subsidiary of a subsidiary) of that entity, a holding company of that entity or any other subsidiary of that holding company, and any affiliated entity of any such entities.

This publication is confidential for the information of the addressee only and may not be reproduced in whole or in part, copies circulated, or disclosed to another party, without the prior written consent of an entity within Cru. Products referred to in this research report may not be eligible for sale in those jurisdictions where an entity within Cru is not authorised or permitted by local law to do so. In particular, Cru does not allow the redistribution of this report to non-professional investors or persons outside the jurisdictions referred to above and Cru cannot be held responsible in any way for third parties who effect such redistribution or recipients thereof. © 2017.